Canakinumab Tapering in Still's Disease
You can reduce – but not stop – canakinumab therapy in patients who are…
View Resource
Canakinumab First FDA-Approved Therapy for Adult-Onset Still's Disease
Yesterday, the FDA approved canakinumab (Ilaris) as treatment for adult-onset Still’s disease (AOSD), the…
View Resource
TNR Grand Rounds – Cytokine Storm Syndromes
This week’s Tuesday Nite Rheumatology featured Dr Randy Cron from the University of Alabama –…
View Resource
High Dose Anakinra Effective in COVID-19
Anakinra was studied in 29 COVID(+) patients with respiratory distress and high inflammatory markers…
View Resource
Earlier Anakinra Initiation Warranted in Still's Disease
An Italian study examined the outcomes in adult onset Still’s disease (AOSD) based on…
View Resource
Canakinumab Use in Periodic Febrile Disorders
A retrospective records review of patients with periodic fever syndromes (PFS) receiving IL-1 inhibitor…
View Resource
Anakinra's Effects on COVID-19 Outcomes
Sporadic reports of anakinra use in COVID-19 infection has hinted is potential; now a metanalysis…
View Resource
Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis
Recurrent pericarditis is a rare, probable autoinflammatory disorder mediated by interleukin-1 (IL-1); and is often…
View Resource